Neuroleptic malignant syndrome and malignant hyperthermia.
D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D002110:Caffeine / Q000494:pharmacology; D005334:Fever / Q000139:chemically induced*; D005476:Fluphenazine / Q000494:pharmacology; D006221:Halothane / Q000494:pharmacology; D006801:Humans; D009119:Muscle Contraction / Q000187:drug effects; D013577:Syndrome
D014150:Antipsychotic Agents; D002110:Caffeine; D005476:Fluphenazine; D006221:Halothane